June 21st 2021, 7:00pm
The Idorsia dual orexin receptor antagonist was accepted by the FDA for review in March 2021 and has shown efficacy in a number of SLEEP 2021 poster presentations.
June 18th 2021, 1:00pm
The medical director of the Ohio State Sleep Medicine Institute discussed the effect of FT218 in treating narcolepsy regardless of stimulant use, as well as its weight-related benefits it brings.
June 17th 2021, 1:00pm
The medical director of the Ohio State Sleep Medicine Institute detailed the progress made within the sleep disorder field in recent years and where it can turn to next.
June 16th 2021, 11:00am
The director of the Sleep-Wake Disorders Center at Montefiore Medical Center detailed the overall state of sleep care and the advantages the investigational FT218 brings to the growing pipeline.
June 13th 2021, 4:00pm
The task force assessed 6 total interventions, all of which received conditional recommendations aside from cognitive behavioral therapy for insomnia, which was strongly recommended.
June 12th 2021, 7:00pm
Results from the START study of medication switching in narcolepsy were presented at the 2021 SLEEP Annual Meeting.
June 12th 2021, 11:00am
Neurology News Network for the week ending June 12, 2021.
June 11th 2021, 5:00pm
The FDA-approved agent demonstrated meaningful reduction in the frequency of cataplexy attacks in adults with narcolepsy, including patients with a high symptom burden.
June 10th 2021, 5:00pm
The program director of the Medstar Georgetown University Hospital Headache Medicine Fellowship program discussed further research to be conducted with the nasal delivery of DHE.